Products Eribulin mesilate + Irinotecan hydrochloride
Eribulin mesilate + Irinotecan hydrochloride Phase 1/2 Completed ⚡ Active Refractory or Recurrent Solid Tumors
Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Mar 5, 2018 → May 17, 2021
About Eribulin mesilate + Irinotecan hydrochloride Eribulin mesilate + Irinotecan hydrochloride is a phase 1/2 stage product being developed by Eisai for Refractory or Recurrent Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03245450. Target conditions include Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT03245450 Phase 1/2 Completed Mar 5, 2018 May 17, 2021 Refractory or Recurrent Solid Tumors
Competing Products 20 competing products in Refractory or Recurrent Solid Tumors
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 perampanel Eisai Phase 2 rabeprazole sodium Eisai Pre-clinical Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Rufinamide Eisai Phase 3 Lenvatinib + Moxifloxacin 400 mg + Placebos (matched to 4 mg and 10 mg lenvatinib capsules). Eisai Phase 1
Other Products from Eisai